Pascal Deschatelets - 21 May 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Scientific Officer
Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Issuer symbol
APLS
Transactions as of
21 May 2025
Net transactions value
+$48,053
Form type
4
Filing time
22 May 2025, 13:19:03 UTC
Previous filing
30 Jan 2025
Next filing
11 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Deschatelets Pascal Chief Scientific Officer C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM /s/ David Watson, attorney-in-fact for Pascal Deschatelets 22 May 2025 0001657720

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $48,053 +12,780 +1.1% $3.76 1,160,496 21 May 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -12,780 -100% $0.000000 0 21 May 2025 Common Stock 12,780 $3.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option was granted on 02/08/2016 and is fully vested.